John Simpson

Recent Posts

Assessing antibody targets and IP risk

Challenge A mid-cap pharma company seeking to establish a biologics pipeline through partnership with a monoclonal antibody development boutique needed an assessment of target opportunities,...
Learn More

Commercial attractiveness of biomarkers for a start-up

Challenge A start-up that had developed a suite of proprietary antibody technologies needed help to identify accessible cell surface proteins for discovery of candidate therapeutic monoclonal...
Learn More

Conducting IP due diligence

Challenge We have conducted multiple due diligence projects, below are three examples:
Learn More

Immunotherapy strategy for a radiotherapy company

Challenge A major player in the radiation oncology market was looking for growth opportunities and had identified cancer immunotherapy as a potential opportunity, given the increasing evidence that...
Learn More

Oncology development plan to support fundraising

Challenge The technology transfer function of a leading cancer research institute needed a development plan for a promising small molecule lead series against a novel anti-invasion/anti-metastasis...
Learn More

Novel Antibody Screening Technology

Technology Consulting: Novel Antibody Screening Technology Alacrita's antibody consultants were asked to help assess the market potential and develop a commercialization strategy for a novel antibody...
Learn More